Atogepant vs. Rimegepant: Effective Migraine Prevention in Japan
- MigraineMind
- Dec 19, 2025
- 1 min read
Research Summary
A study published in Expert Review of Neurotherapeutics compared the effectiveness of atogepant and rimegepant for preventing migraines in Japanese patients. The research used data from three placebo-controlled trials, focusing on changes in mean monthly migraine days (MMDs) and medication use days (MUDs). Atogepant showed a statistically significant reduction in MMDs by 1.33 days and MUDs by 1.97 days over 12 weeks compared to rimegepant. It also improved the Migraine-Specific Quality-of-Life Questionnaire scores significantly. While no major differences were noted in other quality-of-life or safety measures, atogepant outperformed rimegepant in reducing migraines and improving patient quality of life.
Study Details
👥 Research Team: Takizawa T et al.
📚 Published In: Expert Rev Neurother
📅 Publication Date: 2025 Dec 18
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.